AstraZeneca’s (AZN) “Buy” Rating Reaffirmed at Deutsche Bank
Deutsche Bank reissued their buy rating on shares of AstraZeneca (LON:AZN) in a research report report published on Friday morning, Borsen Zeitung reports. The firm currently has a GBX 8,300 ($109.18) target price on the biopharmaceutical company’s stock.
A number of other analysts also recently weighed in on AZN. Credit Suisse Group set a GBX 8,500 ($111.81) target price on AstraZeneca and gave the company a buy rating in a research report on Monday, February 17th. UBS Group set a GBX 6,000 ($78.93) target price on AstraZeneca and gave the company a sell rating in a research report on Monday, March 9th. Morgan Stanley upped their target price on AstraZeneca from GBX 7,400 ($97.34) to GBX 8,100 ($106.55) and gave the company an equal weight rating in a research report on Monday, January 6th. JPMorgan Chase & Co. reiterated an overweight rating on shares of AstraZeneca in a research report on Tuesday, March 10th. Finally, Jefferies Financial Group reiterated a hold rating and set a GBX 7,475 ($98.33) target price on shares of AstraZeneca in a research report on Friday, February 14th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the stock. AstraZeneca currently has a consensus rating of Buy and a consensus target price of GBX 7,862.14 ($103.42).
Shares of LON:AZN traded down GBX 14 ($0.18) during trading on Friday, reaching GBX 6,891 ($90.65). 6,395,407 shares of the company traded hands, compared to its average volume of 2,310,000. The company’s 50 day moving average is GBX 7,243.74 and its two-hundred day moving average is GBX 7,327.66. The firm has a market capitalization of $90.42 billion and a PE ratio of 67.16. The company has a quick ratio of 0.63, a current ratio of 0.86 and a debt-to-equity ratio of 139.95. AstraZeneca has a 52 week low of GBX 5,626 ($74.01) and a 52 week high of GBX 8,227.88 ($108.23).
In other AstraZeneca news, insider Michel Demare acquired 700 shares of the company’s stock in a transaction that occurred on Monday, February 17th. The stock was acquired at an average cost of GBX 7,313 ($96.20) per share, for a total transaction of £51,191 ($67,338.86).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
See Also: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.